Search results
Questions About Melanoma? Harvard Health Publishing Has Answers.
MSN News· 2 days agoWhat are the early stages of melanoma? Answered by Dr. Howard E. Lewine M.D. Chief Medical Editor,...
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND...
The Sun Chronicle· 4 days agoIf approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction cancers as the first and only ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoU.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE PR Newswire TOKYO, May 30, 2024 If approved, the investigational therapy would offer a new treatment option for patients with
... Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line...
Morningstar· 2 days agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC ...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily...
Morningstar· 3 days agoIn 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 ...
Why Is German Biotech Affimed Stock Soaring On Monday?
Benzinga· 18 hours agoOn Saturday, the company announced longer follow-up data from the EGFRwt cohort and initial clinical...
Girls’ periods starting earlier and becoming more irregular: Study
Deseret News via Yahoo News· 5 days agoThe study, led by Dr. Robert Hiatt, who regularly looks at social risk factors for breast cancer,...
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With...
Benzinga· 2 days agoData show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line
A Celebration of Frank London’s Music Will Be Missing One Thing: Him
New York Times· 6 days agoThe trumpeter, composer and bandleader who helped revitalize klezmer is battling cancer. Frank...
How To Stop Skin Cancer
The Harrisonburg Daily News-Record· 7 days agoJerri Lynn Alley, dermatologist and owner of Harrisonburg Dermatology, discusses the dangers of skin cancer, what to look for and provides safety tips to keep you and your ...
